Cargando…
Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives
Despite a preventive vaccine being available, more than 250 million people suffer from chronic hepatitis B virus (HBV) infection, a major cause of liver disease and HCC. HBV infects human hepatocytes where it establishes its genome, the cccDNA with chromosomal features. Therapies controlling HBV rep...
Autores principales: | Taverniti, Valerio, Ligat, Gaëtan, Debing, Yannick, Kum, Dieudonne Buh, Baumert, Thomas F., Verrier, Eloi R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911156/ https://www.ncbi.nlm.nih.gov/pubmed/35268440 http://dx.doi.org/10.3390/jcm11051349 |
Ejemplares similares
-
Targeting Viral cccDNA for Cure of Chronic Hepatitis B
por: Ligat, Gaëtan, et al.
Publicado: (2020) -
Hepatitis B virus–host interactions and novel targets for viral cure
por: Ligat, Gaëtan, et al.
Publicado: (2021) -
Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses
por: Muller, Clotilde, et al.
Publicado: (2021) -
Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection
por: Zhang, Hong, et al.
Publicado: (2020) -
Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target
por: Verrier, Eloi R, et al.
Publicado: (2023)